October 2013

LaunchTrends®: Tafinlar and Mekinist (Malignant Melanoma) (Wave 1) US 2013


BioTrends Research Group is pleased to announce a new syndicated report series, LaunchTrends®: Dabrafenib and Trametinib. This three wave primary research study will follow the launch of Dabrafenib and Trametinib. Wave 1 will track one month post-launch with subsequent waves benchmarking at 6 months and 12 months. Both products are currently under FDA review and based on final approval final methodology will be determined.
LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products from launch through maturity. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and changing market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products. And, they capture the promotional messages and activities of key market players.

Questions Answered in This Report:

  *   Understand awareness of and familiarity with Dabrafenib and Trametinib among Medical Oncologists

  *   Understand the perceived clinical advantages and disadvantages of Dabrafenib compared to other marketed agents used in treating Metastatic Melanoma

  *   Understand the perceived clinical advantages and disadvantages of Trametinib compared to other marketed agents used in treating metastatic melanoma

  *   Understand where Dabrafenib and Trametinib are expected to fit in the treatment algorithm for patients with metastatic melanoma

  *   Track the trial, adoption, and usage trends including anticipated future trends for the treatment of metastatic melanoma

  *   Collect information on the promotional messages and activities being employed by GlaxoSmithKline

  *   Capture interest and familiarity of next generation therapies in development


Sample Frame & Methodology:

- This report will include responses from a random sample of 100 Medical Oncologists

- A qualitative follow up arm includes telephone interviews conducted with a sub-set of 15 survey respondents

To qualify for participation, Medical Oncologists must meet the following criteria:

- In practice between 2 and 30 years

- Minimum of 50 patients with Melanoma personally treated over the last year

- More than 50% of time spent in clinical practice


- Final report in powerpoint format (from each wave)

- Complete set of frequency tables, summary statistics, and cross tabulations (each wave)

- Copies of telephone interviews (as audio files; blinded)

- Proprietary question slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Product Coverage:

Yervoy (ipilimumab), Temodar, Zelboraf (venurafenib), Dacarbazine, Paclitaxel

Companion Reports - BioTrends:

- TreatmentTrends®: Melanoma US

- TreatmentTrends®: Melanoma EU

- LaunchTrends®: Yervoy & Zelboraf US

Companion Reports - Decision Resources:

- Pharmacor Melanoma

- Physician & Payer Forum (EU)

- Patient Flow Model: Melanoma

Search Published Reports

Decision Resources Group brands include: